ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Gevelot

Gevelot (ALGEV)

184.00
0.00
(0.00%)
Closed 21 March 3:30AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
184.00
Bid
184.00
Offer
192.00
Volume
0.00
0.00 Day's Range 0.00
176.00 52 Week Range 250.00
Market Cap
Previous Close
184.00
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
35
Shares Outstanding
752,074
Dividend Yield
2.72%
PE Ratio
10.44
Earnings Per Share (EPS)
17.62
Revenue
157.8M
Net Profit
13.25M

About Gevelot

Sector
Indl, Coml Machy, Equip, Nec
Industry
Special Industry Machinery
Headquarters
Levallois-perret, Hauts-de-seine, Fra
Founded
1820
Gevelot is listed in the Indl, Coml Machy, Equip sector of the Euronext with ticker ALGEV. The last closing price for Gevelot was 184.00 €. Over the last year, Gevelot shares have traded in a share price range of 176.00 € to 250.00 €.

Gevelot currently has 752,074 shares in issue. The market capitalisation of Gevelot is 138.38 € million. Gevelot has a price to earnings ratio (PE ratio) of 10.44.

ALGEV Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10018418518429184.30821918DE
4-4-2.1276595744718819418427187.49440299DE
12-4-2.1276595744718819617635188.64714791DE
26-15-7.53768844221199214176100190.86703716DE
52-48-20.689655172423225017694208.82247465DE
156-4-2.12765957447188250169114196.12730535DE
2603926.8965517241145250140135182.60145319DE

ALGEV - Frequently Asked Questions (FAQ)

What is the current Gevelot share price?
The current share price of Gevelot is 184.00 €
How many Gevelot shares are in issue?
Gevelot has 752,074 shares in issue
What is the market cap of Gevelot?
The market capitalisation of Gevelot is EUR 138.38M
What is the 1 year trading range for Gevelot share price?
Gevelot has traded in the range of 176.00 € to 250.00 € during the past year
What is the PE ratio of Gevelot?
The price to earnings ratio of Gevelot is 10.44
What is the cash to sales ratio of Gevelot?
The cash to sales ratio of Gevelot is 0.88
What is the reporting currency for Gevelot?
Gevelot reports financial results in EUR
What is the latest annual turnover for Gevelot?
The latest annual turnover of Gevelot is EUR 157.8M
What is the latest annual profit for Gevelot?
The latest annual profit of Gevelot is EUR 13.25M
What is the registered address of Gevelot?
The registered address for Gevelot is 6 BOULEVARD BINEAU, LEVALLOIS-PERRET, HAUTS-DE-SEINE, 92300
What is the Gevelot website address?
The website address for Gevelot is www.gevelot-sa.fr
Which industry sector does Gevelot operate in?
Gevelot operates in the SPECIAL INDUSTRY MACHINERY sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DMSBSDiagnostic Medical Systems
0.01 €
(150.00%)
1
ALTHOMetavisio (Thomson Computing)
0.05 €
(39.66%)
4.22M
MLONLOnlineformapro
1.10 €
(20.88%)
1,000
MLACTActivium Group
1.57 €
(19.85%)
1
ENVIEnvipco Holdings NV
6.20 €
(15.89%)
262.42k
SGDDSSpineguard DS
0.0002 €
(-50.00%)
2.8M
PHRPHarol SGPS SA
0.0602 €
(-47.42%)
127.12M
HAFDSHaffner Energy DS
0.0215 €
(-33.64%)
366.16k
MLOCTOctopus Biosafety
0.10 €
(-27.54%)
978
PHXMPHAXIAM Therapeutics SA
1.00 €
(-27.43%)
308.89k
ATOAtos SE
0.0037 €
(0.00%)
437.53M
ALCYBCybergun
0.0002 €
(0.00%)
430.09M
PHRPHarol SGPS SA
0.0602 €
(-47.42%)
127.12M
BCPBanco Comercial Portugues SA
0.5498 €
(-4.71%)
121.43M
ALEUPEuroplasma
0.0111 €
(-13.28%)
98.67M

Discussion

View Full Feed
xodcode xodcode 3 minutes ago
If neither MAA approval comes nor 3-71 results are extremely good, then...there is no NPV calc that makes sense because the stock would be sitting at ~$350m based purely on speculation that the company could run a pair of truly effective PD P3 trials.

So, according to your AVXL analys
AVXL
trunkmonk trunkmonk 4 minutes ago
its actually significant to me, thanks for sharing
FMCC
ilovetech ilovetech 4 minutes ago
Interesting, and the foot dragging MHRA isn't helping the field to stand on its feet.
NWBO
SSKILLZ1 SSKILLZ1 5 minutes ago
VMIR (As Of 3/20/25)

Daily Performance
Value Microcap Index:-0.18%
Value Microcap Index Rebalanced:-0.02%

Overall Performance
Value Microcap Index: -7.80%
Value Microcap Index Rebalanced:-7.46%
SSKILLZ1 SSKILLZ1 5 minutes ago
VMIR (As Of 3/20/25)

Daily Performance
Value Microcap Index:-0.18%
Value Microcap Index Rebalanced:-0.02%

Overall Performance
Value Microcap Index: -7.80%
Value Microcap Index Rebalanced:-7.46%
apontem apontem 6 minutes ago
If anyone's looking for a quick and hassle-free way to access PUSOF, I highly recommend using https://govplus.pissedconsumer.com/review.html govplus . They streamline the whole application process and make it super easy to stay on top of your government services. Definitely worth checking out!
PUSOF
IceCold8 IceCold8 6 minutes ago
I'd love to! How can I profit or recoup my losses when I'm in the red. Seriously,I'd love to get rid of the eye sore!
GMER
Konaploinks Konaploinks 6 minutes ago
Tech . I like your style!😎🤙
IONQ
fuagf fuagf 7 minutes ago
"Jacqui Heinrich", stay tuned.
CCSAB CCSAB 7 minutes ago
Waaa I'm crying and hiding under Mommy's skirt. I'm sure that really worked well for you in 4th grade.
FNMA
harr449 harr449 7 minutes ago
EDGX loading up shares at $6.61 post market.
QUBT
236T568 236T568 7 minutes ago
Republican Rep. Lawler condemns closure of lone Social Security office in district

Rep. Michael Lawler (R-New York) denounced the Social Security Administration’s shift to close the lone agency hearing office in his district, calling the move “a slap in the face” to his constituents.
al44 al44 8 minutes ago
Haters all-

https://media.gettr.com/group5/getter/2025/03/20/21/0dd7b0b5-97d3-395b-73fb-de374d68d115/b764b23f4392f9f55bd2977ad450e17d_768x0.jpg
gitreal gitreal 8 minutes ago
Your anger is misdirected. I am not the one that ripped you off. I'm not the one who has your money.
AABB
norisknorewards norisknorewards 8 minutes ago
https://www.fiercebiotech.com/biotech/uk-cell-therapy-biotech-lays-25-staff-turns-tool-development-over-therapeutics

Maybe Advent can pick up some talent...
NWBO
cadillacdave cadillacdave 8 minutes ago
Yes, the markets should respond well if the policies get implemented and time for them to work.

Stopping the wars along with lower interest rates and cheaper energy should produce good results.
WDDD
al44 al44 9 minutes ago
Here’s a quick lesson for both Americans and Canadians.

Here are just some historic tariffs
Canada hits America with:

Milk: 270%
Cheese: 245%
Butter: 298%
Chicken: 238%
Sausages: 69.9%
Barley seed: 57.8%
Bovine/meat: 26.5
biowin biowin 9 minutes ago
Bioamber is involved with those sectors and as long as my shares remain intact I'm very invested and will be part of the next step transaction and therefore Bioamber is not gone and neither of you or he since you enjoy talking about people's investment in this special company
dinogreeves dinogreeves 11 minutes ago
How will it end is the question? Everything that has a beginning always has an ending, like a book.
MCIC
DesertDrifter DesertDrifter 11 minutes ago
https://scontent-lax3-2.xx.fbcdn.net/v/t39.30808-6/480940268_1166126018860218_4386182022733409292_n.jpg?_nc_cat=111&ccb=1-7&_nc_sid=833d8c&_nc_ohc=5eoNMoxRIy0Q7kNvgHDnB63&_nc_oc=AdnfblkQ3YMuQ2Ad2ofxOQ_l30c6zGGLrPjVkQoUbuYCF_8cQQEYztbCCdUUGCY_j6A&_nc_zt=23&_nc_ht=scontent-lax3-2.xx&_nc_gid=BmKumQQVA1
CCSAB CCSAB 11 minutes ago
Has anyone substantiated the comment related to required CET1 levels only being satisfied via retained earnings? The comment was supposedly made during the Urban Institute roundtable. Was it just related to while in conservatorship they are excluded from doing so?

Current Required
FNMA
PepperJacked PepperJacked 11 minutes ago
You made the claim. Provide it.
IFUS
gerry57 gerry57 11 minutes ago
Yep in total agreement with trial size being a problem in the past and possibly with the 2-71 trial. There were other problems as well cro vetting , disclosure of data, missed timelines . My personal opinion is his only brilliant move these last 3 years was hiring Dr. Jung ,,, try to imagine where w
AVXL
Hoskuld Hoskuld 11 minutes ago
IDK...if MAA is approved then let's say $3b in Revenue in 2028 and work back 3 years - say $15b MC discounted back 20% each year...so roughly $7.5b-$8b market cap? If MAA is not approved but 3-71 results are good then purely based on schizophrenia and approval coming n 2028 and $1b in sales in 2031
AVXL
BigMoneyChalupa BigMoneyChalupa 12 minutes ago
.10+ is my target. Might be a bit choppy on the way but ideally we get a parabolic run past that level. If we hit .25 or .50+ all bets are off. We know these things can go parabolic in a hurry, and with the share structure of ZHUD, anything remains possible.
ZHUD

Your Recent History

Delayed Upgrade Clock